Key Highlights

  • BlinkLab's exploratory SHANK2 study reported statistically significant differences across three participant groups.
  • The clearest result was a reversed sensorimotor gating response in the SHANK2 group.
  • The study used the company's smartphone-based assessment technology.
  • The work is exploratory, so the results are early signals rather than confirmed findings.

BlinkLab Limited (ASX:BB1) is among the healthcare stocks in focus on the ASX today after the digital health company released results from an exploratory study of its smartphone-based assessment technology in people with SHANK2-related autism, a genetic form of the condition. The study, run with the US-based non-profit SHANK2 Foundation, compared eight participants carrying a SHANK2 mutation with 10 unaffected siblings and 99 community participants. BlinkLab reported statistically significant differences in sensorimotor gating, startle habituation and spontaneous sensorimotor behaviour. The results arrived ahead of the company's previously anticipated early 2027 timeframe, and BlinkLab said its separate US Food and Drug Administration program for BlinkLab Dx1 is unchanged.

How the SHANK2 study was run

According to BlinkLab's announcement on 11 November 2026, 20 people were recruited for the study, comprising nine with a SHANK2 mutation and 11 unaffected siblings. Of those, eight SHANK2 participants and 10 siblings completed the 15-minute smartphone assessment. Two people could not complete testing because of discomfort with the headphones or the auditory stimuli used in the test.

To give a wider point of comparison, BlinkLab also used a community group of 99 participants matched by sex, race and age, who completed the same protocol. That design allowed the company to compare the SHANK2 group both with their own family members and with a broader sample.

The assessment is delivered on a smartphone, with sounds played through headphones while the device records the participant's responses.

What the results showed

The headline finding concerned sensorimotor gating, which measures how the brain filters incoming sensory information. In a typical response, a soft sound played just before a louder one reduces the reaction to the louder sound. Community participants and siblings both showed this normal filtering effect, at plus 27.2% and plus 27.8% respectively.

The SHANK2 group showed a reversed result of minus 26.5%. BlinkLab said that represents a difference of about 54 percentage points after adjusting for age and sex.

On startle habituation, which tracks how the response to repeated sounds fades over time, the size of the startle response itself did not differ between groups. However, the SHANK2 group habituated more than community participants when sounds were played at random intervals. When sounds were played at rhythmic intervals, the SHANK2 group habituated more than both community participants and siblings.

For spontaneous sensorimotor behaviour, the SHANK2 group differed from siblings in postural stability, head rotations and mouth openings, and also showed more mouth openings than community participants.

BlinkLab said the findings support assessing how sensorimotor responses adapt over time and are gated, rather than overall responsiveness. The company described the results as biological validation of its platform, while noting that the findings are exploratory and require further validation.

What management said

Chief executive and co-founder Dr Henk-Jan Boele said the company had predicted "a distinct signature across sensorimotor gating, habituation and movement" and that this was observed in the smartphone data.

He also made clear that the commercial case does not rest on the SHANK2 population itself, saying the study "is not about the immediate market size of SHANK2-related autism." Instead, BlinkLab sees the work as relevant to drug developers working on targeted therapies for neurodevelopmental conditions, who need objective ways to measure changes in patients over time.

Why genetic subgroups matter for BlinkLab

SHANK2 is one of a number of genes linked to autism. Because people with the same genetic change may share biological features, researchers studying these groups are looking for measurable markers that could help track a condition or the effect of a treatment.

BlinkLab said the results could support research into digital biomarkers and the use of its technology as an assessment tool in clinical trials. A digital biomarker is a measurement collected through a digital device, such as a smartphone, that reflects a biological or behavioural state. If a quick, home-based test could reliably detect differences in a genetic subgroup, it might be useful for monitoring participants in drug trials.

The study was small, with only eight SHANK2 participants completing testing, which is why the company has framed the results as exploratory. With a group of that size, larger studies would be needed to confirm whether the same patterns appear consistently, and whether they change in a measurable way over time or in response to treatment. BlinkLab has not announced the design or timing of any follow-up study.

The FDA program stays on track

BlinkLab stressed that the SHANK2 study is separate from its main regulatory program. The company is running a pivotal study in the United States to support an FDA 510(k) submission for BlinkLab Dx1, its smartphone-based autism diagnostic aid, which uses the same core technology.

The company said the SHANK2 findings do not change that FDA program. That distinction matters, because the regulatory pathway for Dx1 as a diagnostic aid is a different question from the potential use of the platform as a research or clinical trial tool. A 510(k) submission asks the FDA to clear a device for a defined use, and the evidence for that comes from the pivotal study rather than from exploratory research such as the SHANK2 work. For investors, the main regulatory milestones therefore remain tied to the progress and read-out of the pivotal study.

Key Takeaways

BlinkLab's exploratory SHANK2 study, run with the SHANK2 Foundation, found statistically significant differences between eight participants with a SHANK2 mutation, 10 unaffected siblings and 99 community participants. The clearest result was in sensorimotor gating, where the SHANK2 group showed a reversed response of minus 26.5% compared with normal filtering in the other groups, a gap of about 54 percentage points after adjustment.

The results were delivered ahead of the early 2027 timeframe BlinkLab had flagged, and the company sees potential uses in digital biomarker research and clinical trials. BlinkLab has stressed that the findings are exploratory and require further validation, and that its separate FDA 510(k) program for BlinkLab Dx1 is unchanged.